Estrella Immunopharma Files 8-K
Ticker: ESLAW · Form: 8-K · Filed: Mar 11, 2024 · CIK: 1844417
Sentiment: neutral
Topics: corporate-events, financials, filing
TL;DR
Estrella Immunopharma filed an 8-K on March 8, 2024, updating corporate events and financials.
AI Summary
Estrella Immunopharma, Inc. filed an 8-K on March 8, 2024, reporting other events and financial statements. The company, formerly known as TradeUP Acquisition Corp. until February 4, 2021, is based in Emeryville, California, and operates in the biological products sector.
Why It Matters
This filing provides an update on the company's corporate events and financial status, which is important for investors to understand the company's current standing and any material changes.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks.
Key Players & Entities
- Estrella Immunopharma, Inc. (company) — Registrant
- TradeUP Acquisition Corp. (company) — Former Company Name
- February 4, 2021 (date) — Date of Name Change
- March 8, 2024 (date) — Date of Earliest Event Reported
- 5858 Horton Street, Suite 370 (location) — Business Address
- Emeryville, CA (location) — Business Address City/State
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of March 8, 2024.
When was Estrella Immunopharma, Inc. formerly known as?
Estrella Immunopharma, Inc. was formerly known as TradeUP Acquisition Corp.
On what date did the company change its name from TradeUP Acquisition Corp.?
The company changed its name from TradeUP Acquisition Corp. on February 4, 2021.
What is the business address of Estrella Immunopharma, Inc.?
The business address of Estrella Immunopharma, Inc. is 5858 Horton Street, Suite 370, Emeryville, CA 94608.
What is the SIC code for Estrella Immunopharma, Inc.?
The Standard Industrial Classification (SIC) code for Estrella Immunopharma, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 819 words · 3 min read · ~3 pages · Grade level 13.4 · Accepted 2024-03-08 21:25:16
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ESLA The Nasdaq Stock Mar
- $11.50 — of Common Stock at an exercise price of $11.50 ESLAW The Nasdaq Stock Market LLC
- $1,000,000 — board of directors to repurchase up to $1,000,000 of the Company's common stock as previo
Filing Documents
- ea0201472-8k_estrella.htm (8-K) — 32KB
- 0001213900-24-021186.txt ( ) — 248KB
- esla-20240308.xsd (EX-101.SCH) — 4KB
- esla-20240308_def.xml (EX-101.DEF) — 26KB
- esla-20240308_lab.xml (EX-101.LAB) — 36KB
- esla-20240308_pre.xml (EX-101.PRE) — 25KB
- ea0201472-8k_estrella_htm.xml (XML) — 6KB
01 Other Events
Item 8.01 Other Events. Estrella Immunopharma, Inc. (the "Company") is filing this Current Report on Form 8-K ("Current Report") to provide further detail on the expected timing and method of the Company's share repurchases to be made pursuant to the authorization of its board of directors to repurchase up to $1,000,000 of the Company's common stock as previously announced in the Company's press release issued on January 30, 2024 and included as Exhibit 99.1 to the Company's Form 8-K filed on the same date. As of the date of this Current Report, the Company expects to repurchase shares under such authorization in the open market at prevailing market prices pursuant to a plan complying with the provisions of Rule 10b5-1 and Rule 10b-18 of the Securities Exchange Act of 1934, as amended, using the Company's existing cash reserves during the next 12 months. This Current Report on Form 8-K does not constitute a commitment by the Company to repurchase any specific number of shares, and repurchases may be terminated or modified subsequent to the date of this Current Report on Form 8-K, including with respect to timing, amount and method, in accordance with applicable law based on market conditions and other factors.
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the share repurchases made by the Company. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expects," and similar expressions and the negatives of those terms. These statements relate to future events and involve known and unknown risks, uncertainties, and other factors that could cause actual events to differ materially from those expressed or implied by these forward-looking statements. Factors that may cause actual events to differ materially from current expectations include, among other things, those listed under "Risk Factors" and elsewhere in our recent filings with the Securities and Exchange Commission. The forward-looking statements in this Current Report on Form 8-K represent our views as of the date of this Current Report on Form 8-K. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Estrella Immunopharma, Inc. By: /s/ Peter Xu Name: Peter Xu Title: Chief Financial Officer Date: March 8, 2024 2